Aclaris Therapeutics, Inc. — Form 10-Q
Filed August 6, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 8/100
What the filing says
Neal Walker (CEO) and Kevin Balthaser (CFO) issued standard Sarbanes-Oxley 302 and 906 certifications for the Q2 2026 10-Q ended June 30, 2026, dated August 6, 2026. The certifications attest that financial statements fairly present the company's condition and operations, disclosure controls are effective, and no material weaknesses in internal controls were identified. No specific operational, financial, or strategic changes are disclosed in this exhibit—these are boilerplate compliance documents.
Why this rating
Routine SOX certification exhibits contain no material business substance or disclosures; filed as standard quarterly compliance requirement.
See more from August 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.